Formycon AG (DE:FYB)
XETRA:FYB
Top Page
Formycon AG
(XETRA:FYB)
Select Model
Select Model
Rating:53Neutral
Price Target:
€25.00
▲(40.29% Upside)
Action:ReiteratedDate:11/28/25
Formycon AG's overall stock score of 53 reflects a cautious outlook driven primarily by mixed financial performance, with a strong balance sheet offset by significant profitability and cash flow challenges. Technical indicators suggest moderate bullish momentum, providing some upside potential, but a negative P/E ratio highlights valuation risks in the context of current losses. The score balances stability with operational concerns typical of the biotech sector.
Positive Factors
Balance Sheet Stability
A strong equity base and low leverage indicate financial stability, providing resilience against economic fluctuations and supporting long-term growth.
Negative Factors
Profitability Challenges
Ongoing profitability challenges with negative margins can hinder reinvestment in growth opportunities and affect long-term financial health.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Stability
A strong equity base and low leverage indicate financial stability, providing resilience against economic fluctuations and supporting long-term growth.
Read all positive factors
Formycon AG (FYB) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€314.93M
Dividend YieldN/A
Average Volume (3M)24.96K
Price to Earnings (P/E)―
Beta (1Y)1.16
Revenue Growth-14.84%
EPS Growth-338.52%
CountryDE
Employees250
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.35
Shares Outstanding17,672,928
10 Day Avg. Volume17,772
30 Day Avg. Volume24,962
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.01
Price to Sales (P/S)13.33
P/FCF Ratio-17.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€36.50Price Target Upside104.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.81
Revenue Forecast (FY)€87.50M
Formycon AG Business Overview & Revenue Model
Company Description
Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye disease...
How the Company Makes Money
Formycon AG generates revenue primarily through the development and commercialization of its biosimilar products. The company earns money by entering into licensing agreements and partnerships with larger pharmaceutical firms for the marketing and...
Formycon AG Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
75
Positive
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Mar 2024 | Dec 2022 | Mar 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 51.78M | 69.67M | 77.70M | 42.50M | 36.61M | 34.23M |
| Gross Profit | -514.00K | 14.83M | 23.30M | 12.07M | 10.11M | -2.19M |
| EBITDA | -115.52M | -4.10M | 81.05M | 51.53M | -12.42M | -5.63M |
| Net Income | -169.77M | -125.67M | 75.80M | 35.99M | -13.29M | -6.73M |
Balance Sheet | ||||||
| Total Assets | 742.56M | 771.72M | 890.36M | 853.70M | 70.72M | 75.60M |
| Cash, Cash Equivalents and Short-Term Investments | 27.29M | 41.84M | 27.04M | 9.82M | 25.18M | 42.25M |
| Total Debt | 10.21M | 10.59M | 29.49M | 49.31M | 5.28M | 5.96M |
| Total Liabilities | 334.23M | 309.87M | 387.61M | 497.12M | 14.82M | 7.56M |
| Stockholders Equity | 408.33M | 461.84M | 502.75M | 356.58M | 55.89M | 68.04M |
Cash Flow | ||||||
| Free Cash Flow | 13.75M | -53.16M | -10.88M | -45.75M | -14.48M | -5.86M |
| Operating Cash Flow | 14.48M | -23.22M | -9.85M | -18.99M | -13.54M | -5.21M |
| Investing Cash Flow | -7.26M | -1.46M | -17.38M | -37.07M | -3.93M | -650.00K |
| Financing Cash Flow | -20.75M | 39.48M | 44.44M | 40.85M | 491.00K | 25.75M |
Formycon AG Technical Analysis
Negative
17.82
Price Trends
21.66
Negative
22.68
Negative
24.07
Negative
Market Momentum
-1.27
Positive
38.59
Neutral
46.06
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:FYB, the sentiment is Negative. The current price of 17.82 is below the 20-day moving average (MA) of 19.45, below the 50-day MA of 21.66, and below the 200-day MA of 24.07, indicating a bearish trend. The MACD of -1.27 indicates Positive momentum. The RSI at 38.59 is Neutral, neither overbought nor oversold. The STOCH value of 46.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:FYB.
Formycon AG Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | €1.35B | -51.69 | 4.98% | 0.13% | -18.82% | -113.85% | |
56 Neutral | €299.44M | 23.60 | 4.26% | ― | 9.27% | 65.65% | |
53 Neutral | €314.93M | -2.28 | -39.02% | ― | -14.84% | -338.52% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | €1.35B | -58.15 | 4.98% | ― | -18.82% | -113.85% | |
49 Neutral | €215.16M | 58.01 | 6.55% | 2.71% | -1.64% | 22.60% |
* Healthcare Sector Average
DE:FYB
Formycon AG
17.82
-6.58
-26.97%
DE:BIO
Biotest
36.00
-4.80
-11.76%
DE:BIO3
Biotest
32.00
2.64
9.00%
DE:SBS
STRATEC Biomedical
17.70
-6.69
-27.43%
DE:ILM1
Medios AG
11.74
-0.70
-5.63%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.